Log in

Relevant bibliographies by topics / Neurotrophic biomarker

Contents

Journal articles

Academic literature on the topic 'Neurotrophic biomarker'

Author: Grafiati

Published: 19 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neurotrophic biomarker.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Neurotrophic biomarker"

1

Rowland, Tobias, Benjamin I. Perry, Rachel Upthegrove, et al. "Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses." British Journal of Psychiatry 213, no. 3 (2018): 514–25. http://dx.doi.org/10.1192/bjp.2018.144.

Full text

Abstract:

BackgroundA reliable biomarker signature for bipolar disorder sensitive to illness phase would be of considerable clinical benefit. Among circulating blood-derived markers there has been a significant amount of research into inflammatory markers, neurotrophins and oxidative stress markers.AimsTo synthesise and interpret existing evidence of inflammatory markers, neurotrophins and oxidative stress markers in bipolar disorder focusing on the mood phase of illness.MethodFollowing PRISMA (Preferred Reporting Items for Systematic reviews and Meta-analyses) guidelines, a systematic review was conduc

APA, Harvard, Vancouver, ISO, and other styles

2

Antunes-Lopes, Tiago, Sérgio Carvalho-Barros, Célia-Duarte Cruz, Francisco Cruz, and Carlos Martins-Silva. "Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool?" Advances in Urology 2011 (2011): 1–7. http://dx.doi.org/10.1155/2011/382431.

Full text

Abstract:

Overactive bladder syndrome (OAB) is a highly prevalent urinary dysfunction, with considerable economic and human costs. Clinical diagnosis of OAB is still based on subjective symptoms. A new accurate, objective and noninvasive test to diagnose OAB and assess therapeutic outcome is lacking. Recent studies in lower urinary tract (LUT) dysfunctions, particularly in OAB patients, indicate that urinary proteins (neurotrophins, prostaglandins, and cytokines), serum C reactive protein, and detrusor wall thickness are altered, and such changes could be used as biomarkers of the disease. Nowadays, inc

APA, Harvard, Vancouver, ISO, and other styles

3

Palma-Álvarez, Raul Felipe, Elena Ros-Cucurull, Kristopher Amaro-Hosey, et al. "Peripheral levels of BDNF and opiate-use disorder: literature review and update." Reviews in the Neurosciences 28, no. 5 (2017): 499–508. http://dx.doi.org/10.1515/revneuro-2016-0078.

Full text

Abstract:

AbstractSeveral neurobiological factors are related to opiate-use disorder (OUD), and among them, neurotrophins have a relevant role. Brain-derived neurotrophic factor (BDNF) is a central neurotrophin involved in many neuronal processes, and it has been related to several psychiatric diseases and addictive disorders. BDNF can be measured in plasma and serum; its levels may reflect BDNF concentrations in the central nervous system (CNS) and, indirectly, CNS processes. Hence, peripheral BDNF could be a biomarker in clinical practice. This manuscript explores the findings about peripheral BDNF an

APA, Harvard, Vancouver, ISO, and other styles

4

Almeida, Felipe Borges, Helena Maria Tannhauser Barros, and Graziano Pinna. "Neurosteroids and Neurotrophic Factors: What Is Their Promise as Biomarkers for Major Depression and PTSD?" International Journal of Molecular Sciences 22, no. 4 (2021): 1758. http://dx.doi.org/10.3390/ijms22041758.

Full text

Abstract:

Even though major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are among the most prevalent and incapacitating mental illnesses in the world, their diagnosis still relies solely on the characterization of subjective symptoms (many of which are shared by multiple disorders) self-reported by patients. Thus, the need for objective measures that aid in the detection of and differentiation between psychiatric disorders becomes urgent. In this paper, we explore the potential of neurosteroids and neurotrophic proteins as biomarkers for MDD and PTSD. Circulating levels of the GA

APA, Harvard, Vancouver, ISO, and other styles

5

Mikoteit, T., S. Brand, A. Eckert, E. Holsboer-Trachsler, and J. Beck. "Brain-derived neurotrophic factor as a biomarker of insomnia." European Neuropsychopharmacology 29 (2019): S514—S515. http://dx.doi.org/10.1016/j.euroneuro.2018.11.764.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Roda, Ângela, Inês Chendo, and Mauricio Kunz. "Biomarkers and staging of bipolar disorder: a systematic review." Trends in Psychiatry and Psychotherapy 37, no. 1 (2014): 03–11. http://dx.doi.org/10.1590/2237-6089-2014-0002.

Full text

Abstract:

INTRODUCTION: A growing body of evidence suggests that bipolar disorder (BD) is a progressive disease according to clinical, biochemical and neuroimaging findings. This study reviewed the literature on the relationship between specific biomarkers and BD stages.METHODS: A comprehensive literature search of MEDLINE and PubMed was conducted to identify studies in English and Portuguese using the keywords biomarker, neurotrophic factors, inflammation, oxidative stress, neuroprogression and staging models cross-referenced with bipolar disorder.RESULTS: Morphometric studies of patients with BD found

APA, Harvard, Vancouver, ISO, and other styles

7

Perricos, Alexandra, Kazem Ashjaei, Heinrich Husslein, et al. "Increased serum levels of mBDNF in women with minimal and mild endometriosis have no predictive power for the disease." Experimental Biology and Medicine 243, no. 1 (2017): 50–56. http://dx.doi.org/10.1177/1535370217742600.

Full text

Abstract:

The objective of our pilot clinical, prospective study was to determine the serum levels of mature brain-derived neurotrophic factor, in of women with endometriosis and controls and explore whether mature brain-derived neurotrophic factor is a potential biomarker for the disease. The patients were selected from the Endometriosis Marker Austria prospective cohort study conducted at the tertiary referral certified Endometriosis Center of the Medical University of Vienna. All women underwent laparoscopic surgery because there was a suspicion of endometriosis, or the women had pelvic pain, adnexal

APA, Harvard, Vancouver, ISO, and other styles

8

Eyileten, Ceren, Lucia Sharif, Zofia Wicik, et al. "The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke." Molecular Neurobiology 58, no. 1 (2020): 329–47. http://dx.doi.org/10.1007/s12035-020-02101-2.

Full text

Abstract:

AbstractBrain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors that plays a crucial role in the development of the nervous system while supporting the survival of existing neurons and instigating neurogenesis. Altered levels of BDNF, both in the circulation and in the central nervous system (CNS), have been reported to be involved in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), multiple sclerosis (MS), and ischemic stroke. M

APA, Harvard, Vancouver, ISO, and other styles

9

Rosa, Renata F., Michelle Remião Ugolini-Lopes, Ana Paula Rossi Gandara, et al. "Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS)." Rheumatology 60, no. 1 (2020): 179–87. http://dx.doi.org/10.1093/rheumatology/keaa252.

Full text

Abstract:

Abstract Objectives Cognitive dysfunction (CD) is a poorly understood non-stroke central neurological manifestation in anti-phospholipid syndrome (APS). Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays an important role in neural plasticity and could potentially be a biomarker of CD in primary APS (PAPS). The aim of the study is to assess CD in PAPS patients and to evaluate its association with clinical data, anti-phospholipid antibodies and serum BDNF levels. Methods This cross-sectional study compared 44 PAPS patients and 20 healthy controls matched for age, gender and e

APA, Harvard, Vancouver, ISO, and other styles

10

Abdullahi, Auwal, Steven Truijen, and Wim Saeys. "Neurobiology of Recovery of Motor Function after Stroke: The Central Nervous System Biomarker Effects of Constraint-Induced Movement Therapy." Neural Plasticity 2020 (June 15, 2020): 1–12. http://dx.doi.org/10.1155/2020/9484298.

Full text

Abstract:

Recovery of motor function after stroke involves many biomarkers. This review attempts to identify the biomarker effects responsible for recovery of motor function following the use of Constraint-Induced Movement Therapy (CIMT) and discuss their implications for research and practice. From the studies reviewed, the biomarker effects identified include improved perfusion of motor areas and brain glucose metabolism; increased expression of proteins, namely, Brain-Derived Neurotrophic Factor (BDNF), Vascular Endothelial Growth Factor (VEGF), and Growth-Associated Protein 43 (GAP-43); and decrease

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!